Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 May;28(3):585-596.
doi: 10.1007/s10741-022-10238-6. Epub 2022 May 6.

Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence

Affiliations
Review

Diabetes leading to heart failure and heart failure leading to diabetes: epidemiological and clinical evidence

Alberto Palazzuoli et al. Heart Fail Rev. 2023 May.

Abstract

Type 2 diabetes mellitus (T2DM) is a risk factor that plays a major role in the onset of heart failure (HF) both directly, by impairing cardiac function, and indirectly, through associated diseases such as hypertension, coronary disease, renal dysfunction, obesity, and other metabolic disorders. In a population of HF patients, the presence of T2DM ranged from 20 to 40%, according to the population studied, risk factor characteristics, geographic area, and age, and it is associated with a worse prognosis. Finally, patients with HF, when compared with those without HF, show an increased risk for the onset of T2DM due to several mechanisms that predispose the HF patient to insulin resistance. Despite the epidemiological data confirmed the relationship between T2DM and HF, the exact prevalence of HF in T2DM comes from interventional trials rather than from observational registries aimed to prospectively evaluate the risk of HF occurrence in T2DM population. This review is focused on the vicious cycle linking HF and T2DM, from epidemiological data to prognostic implications.

Keywords: Epidemiology; Heart failure; Prognosis; Type 2 diabetes mellitus.

PubMed Disclaimer

Conflict of interest statement

M. Iacoviello received honoraria as a consultant in advisory boards from AstraZeneca, Boehringer Ingelheim, Lilly, Merck Serono, Novartis, and Vifor Pharma. A. Palazzuoli received honoraria as a consultant from Menarini and Novartis.

Figures

Fig. 1
Fig. 1
Traditional and emerging risk factors that explain the increased risk of adverse events in patients with HF and associated diabetes
Fig. 2
Fig. 2
Pathophysiologic background leading to diabetes in heart failure patients and the influence of heart failure therapy on the risk of developing diabetes

Similar articles

Cited by

References

    1. Morrish JN, Wang S-L, Stevens KL, Fuller HJ, Keen H (2001) Mortality and causes of death in the WHO multinational study of vascular disease in diabetes. Diabetologia 44:S14–S21. 10.1007/pl00002934 - PubMed
    1. Garcia MJ, McNamara PM, Gordon T, Kannel WB. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study Diabetes. 1974;23:105–111. doi: 10.2337/diab.23.2.105. - DOI - PubMed
    1. Nichols GA, Gullion CM, Koro CE, Ephross SA, Brown JB (2004) The incidence of congestive heart failure in type 2 diabetes: an update. Diabetes Care 27:1879–1884. 10.2337/diacare.27.8.1879 - PubMed
    1. McMurray JJ, Gerstein HC, Holman RR, Pfeffer MA. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2014;2:843–851. doi: 10.1016/S2213-8587(14)70031-2. - DOI - PubMed
    1. Fitchett DH, Udell JA, Inzucchi SE (2017) Heart failure outcomes in clinical trials of glucose-lowering agents in patients with diabetes. Eur J Heart Fail 19:43–53. 10.1002/ejhf.633 - PubMed